
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Graduate Center for Toxicology, University of Kentucky, Lexington, Kentucky; 2 Department of Pathology and Laboratory Medicine Service, William S. Middleton Veterans Memorial Hospital, University of Wisconsin, Madison, Wisconsin; and 3 Faculty of Medical Technology, Mahidol University, Bangkok, Thailand
Requests for reprints: Daret K. St. Clair, Graduate Center for Toxicology, University of Kentucky, 454 Health Sciences Research Building, Lexington, KY 40536. Phone: 859-257-3956; Fax: 859-323-1059. E-mail: dstcl00{at}uky.edu
Cardiomyopathy is a major dose-limiting factor for applications of Adriamycin, a potent chemotherapeutic agent. The present study tested the hypothesis that increased tumor necrosis factor (TNF)-
signaling via its receptors protects against Adriamycin-induced cardiac injury. We used mice in which both TNF receptor I and II have been selectively inactivated (DKO) with wild-type mice as controls. Morphometric studies of cardiac tissue following Adriamycin treatment revealed greater ultrastructural damage in cardiomyocyte mitochondria from DKO mice. Biochemical studies of cardiac tissues showed cytochrome c release and the increase in proapoptotic protein levels, suggesting that lack of TNF-
receptor I and II exacerbates Adriamycin-induced cardiac injury. The protective role of TNF receptor I and II was directly confirmed in isolated primary cardiomyocytes. Interestingly, following Adriamycin treatment, the levels of Fas decreased in the wild-type mice. In contrast, DKO mice had an increase in Fas levels and its downstream target, mitochondrial truncated Bid. These results suggested that TNF-
receptors play a critical role in cardioprotection by suppression of the mitochondrial-mediated associated cell death pathway. [Mol Cancer Ther 2006;5(2):2619]
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Note: The current address for Y-C. Lien is Center for Radiological Research, College of Physicians and Surgeons, Columbia University, New York, NY 10032. The current address for S-M. Lin is Nutritional Science, Chung Hwa College of Medical Technology, 717 Tainan, Taiwan. The current address for Q. Zhao is Department of Biochemistry, Guangzhou Medical College, 510182 Guangzhou, China.
Received 9/27/05; revised 11/ 3/05; accepted 11/22/05.
Commentary
Mol. Cancer Ther. 2006 5: 1385-1386.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |